Founder · Austin R&D
Brain-computer interface research and development. First human participants received the N1 Telepathy implant in 2024; ongoing PRIME study enrollment for motor-impairment indications.
Relocated operations from Fremont, California to Austin-area facilities starting 2022. Manufacturing, clinical engineering, and executive offices now run out of Central Texas.